Spyre Therapeutics (SYRE) stock

Antibody treatments , market cap $9.2B

Antibody treatments

Market cap $9.2B

$95.51

-1.09%

As of Monday's close · Live for Pro members at the open

Quality Score

Average

In its industry

#54of 291

Biotech

Checks firing

6of 14

Trending up

From 52-week high

-13.3%

Above the 200-day

SYRE's Quality Score fell 1 point on Mon, Nov 2, to 7. Its price slipped further from its high of the past year.

Follow SYRE's trial news. Pro members can get an alert when Spyre Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when SYRE files news on its trialsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextQ4 2026“Topline data for SPY072 in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) on track for Q4 2026…”Trial data · SEC filing · Aug 25

Why is SYRE up?

Up 298% in a year while the S&P 500 rose 12%.

Its loss narrowed from $208.0M in fiscal 2024 to $155.2M in fiscal 2025.

Sources: Price history, Oct 30, 2026; Annual reports, Dec 31, 2025

How the business stands, the timeline, and its peers, for Pro members.

Key facts on SYRE

Key facts on SYRE
Outperforming	Up 294% in a year vs the S&P's +11%
Latest filing	8-K, Oct 7 Signed a material agreement

1 more reason behind SYRE's 7, free with an account →2 more reasons behind SYRE's 7, for Pro members.

SYRE in the news

ReportReports tomorrow, after the close. Every 3 months, a company tells everyone how much it sold and earned. It rose after 2 and fell after 2 of its last 4 reports, +4.0% on average. Past reports ›

SYRE catalysts

Coming up

After its last 4 reports it closed +4.0% on average, higher 2 of 4 times.

3 more coming up and 5 past catalysts since 2026, with sizes and sources, for Pro members.Get in free →

What's next for SYRE, and how long its cash lasts

Next step the company has named

Q4 2026“Topline data for SPY072 in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) on track for Q4 2026 and for SPY072 in combination with IL17-A/F in hidradenitis suppurativa (HS) in…”Trial data · SEC filing · Aug 25

What it means: the first look at a trial’s main results, as the company reports them.

Lead program: SPY072 · Hidradenitis Suppurativa (HS) · Phase 2
Its trial: SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)Phase 2 · Recruiting · 150 people · main data estimated Oct 2027 · NCT07766005

4 more trials, 1 with data due this year, 2 more milestones and 43 filings, for Pro members.

Cash runway

The company says its cash lasts into the second half of 2029 (8-K, Aug 4).

That is the company's estimate. Our arithmetic on its latest balance sheet reads differently, so we show its words, not ours.

For Pro members: the cash on hand, the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3ASR, filed Jun 26, 2026)
At-the-market share sales program (S-3ASR, filed Jun 26, 2026)

For Pro members: 4 raises and their amounts, and the share count against a year ago.

Insiders

An officer, Heidy King-Jones, sold 28,933 shares on Oct 1, under a planned sale. 28 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Cameron Turtle buys or sells

For Pro members: every trade, and Cameron Turtle’s 21 filings and quotes.

Get an alert when SYRE files news on its trialsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 20 daysFDA decisionIn 20 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $385MDeramiocelFDA decision due (PDUFA)
In 20 daysFDA decisionIn 20 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $1.0BMolgramostimFDA decision due (PDUFA)
In 50 daysFDA decisionIn 50 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.9BLorundrostatFDA decision due (PDUFA)

11 more FDA dates and 102 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 143 dates, ranked →

Why SYRE scores 7

Averagefor quality, not price, 6 of 14 chart checks firingWhat the Quality Score means

Well above its recent run. SYRE scores 7 today, against a median of 3 over its last 20 recorded sessions.

+6Chart checks 6 of 14 firing right now, one point each
+2Long-term trend above a rising 200-⁠day average

Run-up adds
Dilution subtractsNew shares over the year: -1 at 10% more, -2 at 25% more.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Size, Profit, Growth, Volatility, Persistence, and News.

What every line is worth, and the reason behind it, on SYRE and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 8:40 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

Alert me when SYRE's Quality Score turns up

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Here is what Pro members see.

The same page for Pro members, on AMD
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on SYRE and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

SYRE has 6 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on SYRE, and all 14 on every stock.Get in free →

SYRE RSI today: 57.2, above its 50-day and 200-day averages

Not scored

Not in the Quality Score: over 20 years of tests, 2006 to 2026, they added no edge.

RSI 1457.2
Above 50, below 70.
MACD (12, 26, 9)Above signal
Crossed above its signal line 9 sessions ago.
50-day average$89.84
The price is 6.3% above it.
200-day average$73.53
The price is 29.9% above it.
50/200 crossGolden cross
The 50-day crossed above the 200-day on Oct 22, 2025.
ADX 1417.3
Under 25, with +DI above -DI.
Support$92.37
Swing low from Jul 17, 3.3% below the price.
Resistance$102.06
Swing high from Jun 23, 6.9% above the price.
52-week high$110.17
From Aug 19, 15.4% above the price.
52-week low$21.14
From Nov 7, 2025, 77.9% below the price.
Chart patternNone
No triangle, channel, or wedge in the last year.
Bollinger Bands (20, 2)Inside
The bands run from $73.71 to $102.89.
Volume0.6x
Against its 20-day average, for the time of day.

The deep dive on SYRE

What it does and how it makes money1 findingFor Pro members1 finding on what SYRE does and how it makes money, for Pro members
What changed in its filings5 findingsA new heading in its "Risk Factors" this year: "We may be negatively impacted by changes in law or other policy, including healthcare reform initiatives ." (10-K for fiscal 2025; not in fiscal 2024's)SEC filing · Feb 19, 2026, against the one of Feb 27, 2025
Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades SYRE, for Pro members
Against its closest peers4 peersCash and short-term investments: SYRE $1.15B, VRDN $982M, PTGX $783M, RCUS $702M.

7 more findings on SYRE, each with its source, for Pro membersGet in free →

How SYRE ranks in Biotech

SYRE is #54 of 291 by Quality Score.

How SYRE ranks in Biotech
1	KNSAKiniksa Pharmaceuticals International	6/14	21
2	TGTXTG Therapeutics	8/14	19
3	AMGNAmgen	5/14	19
	STROSutro Biopharma		Open for its score
	SUPNSupernus Pharmaceuticals		Open for its score
	TAKTakeda Pharmaceutical		Open for its score
	TARAProtara Therapeutics		Open for its score
54	SYRESpyre Therapeutics	6/14	7

Cash and short-term investments: SYRE $1.15B, VRDN $982M, PTGX $783M, RCUS $702M.

When does SYRE report earnings, and what happens after?

Reports Tue Nov 3, after the close (tomorrow). Confirmed.

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What SYRE reported on Aug 4, 2026

The quarter

The figures are not read from the release yet.

“The increase was primarily driven by higher manufacturing and clinical trial expenses, as well as higher headcount costs.”

The filing on EDGAR

Where the sales came from

SYRE's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

“The increase was primarily driven by higher headcount costs.”

From its results filing (SEC filing · Aug 4)

The numbers

Market value: $9.2B; today
Sales: $0; last fiscal year
Loss: $155M; last fiscal year

1 more figure, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on SYRE: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.Get in free →

+14.3%+2.7%-0.6%

Feb 19May 5Aug 4

Reported	When	Gap	Reaction	5 sessions
Aug 4, 2026After close	After close	0.0%	-0.6%	-2.1%
May 5, 2026Before open	Before open	+2.2%	+2.7%	+10.6%
Feb 19, 2026After close	After close	+0.0%	+14.3%	+14.1%

SYRE closed higher after 2 of its last 4 reports.

All 4 reports, and SYRE's Quality Score going into each

Everyone reporting earnings this week

SYRE sales and profit by year

Sales and profit by year

Sales grew in one of the last seven years, to $0 in 2025. It lost money in each of the eight years.

SYRE share count over time

12 times the count a year earlier.

Weighted shares, quarter to Sep 30, 2024, both from one filing

Shares of SYRE outstanding, as filed
Shares outstanding	As of
88.2M	Jul 28, 2026
86.8M	Apr 28, 2026
78.5M	Feb 12, 2026
77.6M	Oct 29, 2025

Offerings, shelves, and splits of SYRE, from its filings
From its filings	Filed
Raised $350M in a sale of shares, about 4% of its market value	Oct 6, 2026
Registered shares for a later sale (S-3ASR)	Jun 26, 2026
Raised $403M in a sale of shares, about 4% of its market value	Apr 16, 2026
Registered shares for a later sale (S-3)	Feb 19, 2026

7 more offerings on file, for Pro members.

Insiders trading SYRE

SYRE insider trades

2 insiders sold $401M across 3 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellScott L. Burrows$871KChief Financial Officerat $87.14 on Jun 25, filed Jun 26

SellScott L. BurrowsChief Financial Officer$871Kat $87.14 on Jun 25, filed Jun 26

All 3 insider filings on SYRE from the last six months, for Pro members.Get in free →

All SYRE insider trades

SYRE's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Cameron TurtleChief Executive Officer · 12 trades
Scott L. BurrowsChief Financial Officer · 12 trades
Sheldon SloanChief Medical Officer · 4 trades
Heidy King-JonesOfficer · 3 trades
Michael Thomas HendersonDirector · 2 trades
Peter Evan HarwinDirector · 1 trade
Tomas KiselakDirector · 1 trade
Jeffrey W. AlbersDirector · 1 trade

See insider trades by person

Which ETFs hold SYRE?

In ETFs: SYRE is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Spyre Therapeutics

Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

112 employeesWaltham, MAspyre.com

What Spyre Therapeutics says it competes with

“We expect to face intense competition from other biopharmaceutical companies that are developing agents for the treatment of inflammatory diseases.”

From its annual report, SEC filing · Feb 19, 2026

2 more sentences and what it says it does, for Pro membersGet in free →

SYRE's score card

Spyre Therapeutics (SYRE): Quality Score 7, Average, #54 of 291 in Biotech, with its price, on Breakaway — The picture a link to this page shows when it is shared.

Pro members see every line of every stock's score.

What would move SYRE's score: 6 things
13 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawayJun 26Scott L. Burrows sold SYRE$871K at $87.14, filed Jun 26

Alerts are optional.

See SYRE's 14 chart checks

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Straight Answers

As of Nov 2, 2026: SYRE's Quality Score is 7 (Average), #54 of 291 in Biotech. Insiders sold $401M in the last 6 months (Form 4).

Is SYRE a good stock to buy? What its Quality Score says

SYRE scores 7 today, which Breakaway calls Average. It is #54 of 291 in Biotech by Quality Score, with 6 of 14 chart checks firing. Up 298% in a year while the S&P 500 rose 12%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is SYRE's Quality Score?

SYRE scores 7 today, which Breakaway calls Average (6 to 10). That is #54 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind SYRE's 7.

Are insiders buying SYRE?

2 insiders sold $401M across 3 filings in the last 6 months. No open-⁠market buys on record. The newest is Scott L. Burrows, Chief Financial Officer, who sold $871K on Jun 25. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.